IDH1 and central nervous system cancer: Three prospective trials (NCT01358058, NCT03180502, NCT02797366, sponsored by NRG Oncology, Sweden and the United States) are conducted regarding proton therapy treating WHO grade 3 glioma with different molecular pathology (IDH1 mutation or 1p/19q codeletion) (see Table 5).